Epizyme Inc. (EPZM)

13.04
0.61 4.50
NASDAQ : Health Technology
Prev Close 13.65
Open 13.64
Day Low/High 12.93 / 13.64
52 Wk Low/High 5.14 / 16.59
Volume 344.30K
Avg Volume 875.10K
Exchange NASDAQ
Shares Outstanding 90.83M
Market Cap 1.25B
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Epizyme Reports Updated Data From Phase 2 Trial Of Tazemetostat For Epithelioid Sarcoma At 2019 ASCO Annual Meeting

Epizyme Reports Updated Data From Phase 2 Trial Of Tazemetostat For Epithelioid Sarcoma At 2019 ASCO Annual Meeting

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported updated data on tazemetostat from the epithelioid sarcoma cohort of its ongoing Phase 2 study in patients with molecularly defined...

Epizyme Submits New Drug Application To The U.S. FDA For Tazemetostat For The Treatment Of Patients With Epithelioid Sarcoma

Epizyme Submits New Drug Application To The U.S. FDA For Tazemetostat For The Treatment Of Patients With Epithelioid Sarcoma

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that it has submitted a New Drug Application (NDA) to the U.

Epizyme To Present At Jefferies 2019 Healthcare Conference

Epizyme To Present At Jefferies 2019 Healthcare Conference

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will present at the Jefferies 2019 Healthcare Conference on June 5,...

Epizyme Announces New Tazemetostat Clinical Data To Be Presented In Oral Sessions At Multiple Upcoming Medical Meetings

Epizyme Announces New Tazemetostat Clinical Data To Be Presented In Oral Sessions At Multiple Upcoming Medical Meetings

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that new data from the epithelioid sarcoma and follicular lymphoma cohorts of the company's ongoing Phase 2 clinical trials of...

Epizyme Provides Business Update And Reports First Quarter 2019 Financial Results

Epizyme Provides Business Update And Reports First Quarter 2019 Financial Results

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported first quarter 2019 financial results.

First Week Of EPZM November 15th Options Trading

First Week Of EPZM November 15th Options Trading

Investors in Epizyme Inc. saw new options become available this week, for the November 15th expiration.

Epizyme Announces Closing Of Concurrent Public Offerings And Full Exercise Of Underwriter's Option To Purchase Additional Shares

Epizyme Announces Closing Of Concurrent Public Offerings And Full Exercise Of Underwriter's Option To Purchase Additional Shares

Epizyme, Inc. (Nasdaq: EPZM), a late-stage company developing novel epigenetic therapies, today announced the closing of its two concurrent underwritten public offerings of 11,500,000 shares of its common stock and 350,000 shares of its non-voting Series...

Epizyme Announces Pricing Of Concurrent Public Offerings Of Common Stock And Series A Preferred Stock

Epizyme Announces Pricing Of Concurrent Public Offerings Of Common Stock And Series A Preferred Stock

Epizyme, Inc. (Nasdaq:EPZM), a late-stage company developing novel epigenetic therapies, today announced the pricing of two concurrent underwritten public offerings of (i) 10,000,000 shares of its common stock and (ii) 304,348 shares of its non-voting...

Epizyme Announces Proposed Concurrent Public Offerings Of Common Stock And Series A Preferred Stock

Epizyme Announces Proposed Concurrent Public Offerings Of Common Stock And Series A Preferred Stock

Epizyme, Inc. (Nasdaq: EPZM), a late-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock in two concurrent but separate underwritten...

Epizyme Announces Presentations At Upcoming March Investor Conferences

Epizyme Announces Presentations At Upcoming March Investor Conferences

Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the following March investor conferences: Cowen 39 th Annual Health Care Conference on Tuesday,...

Epizyme Provides Business Update And Reports Fourth Quarter And Full Year 2018 Financial Results

Epizyme Provides Business Update And Reports Fourth Quarter And Full Year 2018 Financial Results

Epizyme, Inc. (Nasdaq: EPZM), a late-stage company developing novel epigenetic therapies, today provided business and pipeline updates and reported fourth quarter and full year 2018 financial results.

Epizyme Announces Date Of Fourth Quarter And Full Year 2018 Results And Upcoming Presentation At The 8th Annual SVB Leerink Global Health Care Conference

Epizyme Announces Date Of Fourth Quarter And Full Year 2018 Results And Upcoming Presentation At The 8th Annual SVB Leerink Global Health Care Conference

Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call in conjunction with the announcement of its fourth quarter and full-year 2018...

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

The Dow Jones Industrial Average is higher Monday amid improved prospects for a trade deal between the U.S. and China.

First Week Of August 16th Options Trading For Epizyme (EPZM)

First Week Of August 16th Options Trading For Epizyme (EPZM)

Investors in Epizyme Inc. saw new options begin trading this week, for the August 16th expiration.

Epizyme Announces Registration Path For Tazemetostat For Follicular Lymphoma And Provides Pipeline Updates And 2019 Guidance

Epizyme Announces Registration Path For Tazemetostat For Follicular Lymphoma And Provides Pipeline Updates And 2019 Guidance

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced a comprehensive set of pipeline updates, including that the company has identified a path to submission for accelerated approval of tazemetostat...

Epizyme Earns $8 Million Milestone Payment From GlaxoSmithKline For Initiation Of Clinical Development For First-in-Class PRMT1 Inhibitor

Epizyme Earns $8 Million Milestone Payment From GlaxoSmithKline For Initiation Of Clinical Development For First-in-Class PRMT1 Inhibitor

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced it has earned an $8 million milestone payment from GlaxoSmithKline (GSK).

Epizyme Is Now Oversold (EPZM)

Epizyme Is Now Oversold (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Epizyme Announces Conference Call To Discuss Corporate Updates

Epizyme Announces Conference Call To Discuss Corporate Updates

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a conference call to discuss corporate updates today at 8:30 a.

Epizyme Reports Third Quarter 2018 Financial Results And Tazemetostat Progress

Epizyme Reports Third Quarter 2018 Financial Results And Tazemetostat Progress

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today reported financial results for the third quarter of 2018 and provided updates on its tazemetostat clinical development program.

Oversold Conditions For Epizyme (EPZM)

Oversold Conditions For Epizyme (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Epizyme Reports Positive Data On Tazemetostat In Epithelioid Sarcoma From Its Phase 2 Trial Cohort At ESMO

Epizyme Reports Positive Data On Tazemetostat In Epithelioid Sarcoma From Its Phase 2 Trial Cohort At ESMO

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced positive interim data from the fully enrolled epithelioid sarcoma cohort of its ongoing Phase 2 study of its lead candidate tazemetostat, a...

Epizyme To Present Updated Data On Tazemetostat From Full Phase 2 Study Cohort In Epithelioid Sarcoma At ESMO

Epizyme To Present Updated Data On Tazemetostat From Full Phase 2 Study Cohort In Epithelioid Sarcoma At ESMO

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, announced today that updated efficacy and safety data from the fully enrolled cohort of epithelioid sarcoma (ES) patients in its ongoing Phase 2 trial of...

Epizyme Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriter's Option To Purchase Additional Shares

Epizyme Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriter's Option To Purchase Additional Shares

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the closing of its underwritten public offering of 9,583,334 shares of its common stock at a public offering price of $9.

Interesting EPZM Put And Call Options For May 2019

Interesting EPZM Put And Call Options For May 2019

Investors in Epizyme Inc. saw new options begin trading this week, for the May 2019 expiration.

Epizyme Announces Pricing Of Public Offering Of Common Stock

Epizyme Announces Pricing Of Public Offering Of Common Stock

Epizyme, Inc. (Nasdaq:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the pricing of an underwritten public offering of 8,333,334 shares of its common stock at a price of $9.

Epizyme Announces Proposed Public Offering Of Common Stock

Epizyme Announces Proposed Public Offering Of Common Stock

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Epizyme Announces The U.S. Food And Drug Administration Lifts Partial Clinical Hold On Tazemetostat Clinical Program

Epizyme Announces The U.S. Food And Drug Administration Lifts Partial Clinical Hold On Tazemetostat Clinical Program

Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the U.

Epizyme To Participate In Upcoming Investor Conferences

Epizyme To Participate In Upcoming Investor Conferences

Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will present at the following upcoming investor conferences: Citi's 13th Annual Biotech Conference in Boston - Panel discussion...

TheStreet Quant Rating: D (Sell)